Day: December 17, 2025

Almere, The NetherlandsDecember 17, 2025 ASM International N.V. (Euronext Amsterdam: ASM) today announced its intention to invest in a new facility in the Netherlands to support future growth. As part of this strategic investment, ASM signed a Head of Terms with the Municipality of Almere and the Province of Flevoland in the presence of minister Karremans of Economic Affairs. The planned facility in Almere will serve as ASM’s new global headquarters and include a state-of-the-art R&D center, a dedicated training hub, and part of the group’s product development operations. Over the coming years, ASM expects to invest several hundred million euros in this project, marking a significant expansion of its presence and activities in the Netherlands.This investment aligns with ASM’s Growth-through-Innovation strategy and supports its ambition...

Patent Protects Foundational Cloud-Based Architecture Enabling Scalable AI Video Intelligence, Remote Monitoring, and Security Analytics PALO ALTO, CA, Dec. 17, 2025 (GLOBE NEWSWIRE) — Cloudastructure, Inc. (Nasdaq: CSAI) (“we,” “us,” “our,” “Cloudastructure” or the “Company”), a leader in AI-powered video surveillance, remote monitoring, and remote guarding services, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for U.S. Patent Application No. 18/133,167, titled “Methods and Systems Improving Network Performance for Video Surveillance.” The patent protects core innovations that underpin modern cloud-based AI video surveillance, security analytics, and remote guarding platforms. The patent names Cloudastructure Founder Rick Bentley, CTO Gregory Rayzman, and Senior...

Expansion Builds on Legacy of Rush Limbaugh and Honors the Enduring Impact of Charlie Kirk CAMARILLO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) — Salem Media, Inc. (OTCQX: SALM) today announced a significant expansion of its Salem Radio Network (SRN) weekday lineup, with two prominent voices in conservative media stepping into the historic 12–3 p.m. ET time slot beginning Monday, January 5. Alex Marlow, Editor-in-Chief of Breitbart News, will anchor the 12–1 p.m. ET hour, followed by Scott Jennings, CNN political commentator and longtime conservative strategist, who will expand his current SRN program to two hours, airing from 1–3 p.m. ET. The midday block is among the most storied in talk radio history, having previously been home to Rush Limbaugh and, most recently, Charlie Kirk, whose influence on a generation of Americans continues...

New data reveals pessimism is on the rise as cost-of-living pressures and housing affordability reshape consumer expectations NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) — New research from Cint, a global leader in research and measurement technology, reveals a growing sense of pessimism among consumers as they reflect on the past quarter century, with rising costs, financial insecurity, and declining trust in brands shaping how people view the state of the world today. According to Cint’s “The Quarter-Century Crisis Report,” a majority of U.S. consumers now believe life has gotten worse compared to 25 years ago. This marks a notable shift even just from earlier 2025 sentiment, underscoring how quickly consumer perceptions can change in response to economic and social pressures. Key findings from the study include:54% of U.S. consumers...

Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com PLAINVIEW, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) — Vaso Corporation (OTCQX: VASO) announced today that its wholly owned subsidiary, Vaso Diagnostics, Inc. d/b/a VasoHealthcare, has signed an amendment to the sales representation agreement with GE HealthCare (NASDAQ: GEHC) to extend the term of the agreement through December 31, 2030. This is the fifth time the parties have agreed to extend the term of the agreement and establishes a significant milestone in this longstanding collaboration, which began in May 2010. By virtue of the latest extension, the relationship will ultimately span over 20 years, reinforcing the shared commitment...

NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW CALGARY, Alberta, Dec. 17, 2025 (GLOBE NEWSWIRE) —  Unless otherwise stated, all numbers in this press release are presented in Canadian dollars. Alaris Equity Partners Income Trust (“Alaris” or the “Trust“) (TSX: AD.UN) is pleased to announce that it has completed its previously announced offering of convertible unsecured senior debentures (“Debentures“) with a syndicate of underwriters (the “Underwriters”) led by National Bank Capital Markets and CIBC Capital Markets and including Desjardins Capital Markets, Acumen Capital Finance Partners Limited, Raymond James Ltd., RBC Capital Markets, Scotiabank and Cormark Securities Inc. A total of $115 million...

VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (“GoldHaven” or the “Company”) is pleased to provide a comprehensive update on its inaugural diamond drilling program at the Copeçal Project, further to its previous press releases announcing the commencement of drilling, the intersection of sulphide mineralisation in Hole COPE-PDH-004, and the subsequent drilling of a follow-up Hole COPE-PDH-009. HighlightsInaugural diamond drilling program successfully completed at the Copeçal Project, marking the first-ever diamond drilling campaign on the property, with nine holes totaling 1,085.7 metres completed. Sulphide mineralisation intersected at the Eastern Gold-in-Soil Anomaly, including chalcopyrite–pyrite over ~30 metres in Hole COPE-PDH-004 and bornite–chalcopyrite–pyrite over ~5 metres in...

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that it has initiated a first-in-human Phase 1 clinical study of ACCG-2671, the company’s lead oral small molecule amylin receptor agonist for the treatment of obesity. ACCG-2671 was designed via the company’s next generation structure-based drug discovery platform to harness the established metabolic benefits of amylin biology in an oral, once-daily small molecule, with the potential to improve scalability, combinability, and patient access. “We believe amylin-based therapies are poised to become an important next-generation component of the treatment landscape for obesity and...